LYTIR

Company · ATRA

Atara Biotherapeutics, Inc.

Nasdaq's symbol directory lists ATRA on Nasdaq as “Atara Biotherapeutics, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 1 occasion ($1.0M); insiders sold on 1 occasion ($41K); 2 filings by holders of 5% or more.

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $1.0M in total; Insider sales: $41K in total.Aug: Insider sales $41KSep: Insider purchases $1.0MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $1.0MInsider sales below: $41K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Brian N. Cherry bought on 1 day latest Sep 4, 2026 bought $1.0M
  2. Nguyen AnhCo, President and CEO sold on 1 day latest Aug 17, 2026 sold $41K
Every trade (2)
  1. BUYBrian N. Cherry bought Sep 4, 2026 104,166 shares filing $1.0M
  2. SELLNguyen AnhCo, President and CEO sold Aug 17, 2026 5,062 shares filing $41K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Point72 Asset Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive filing 7.6%
  2. Redmile Group, LLC filed Jul 24, 2026 Schedule 13D/A may seek influence 950,994 shares filing 9.9%

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.